TheraRadar
Data updated: Mar 29, 2026

ZTALMY

GANAXOLONE GABA A Receptor Positive Modulators
Neurology Approved 2022-03-18

ZTALMY (ganaxolone) is a neuroactive steroid indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder. It is approved for use in pediatric and adult patients 2 years of age and older. This medication provides a therapeutic option specifically for managing the seizure activity linked to this genetic condition.

Source: FDA Label • MARINUS • Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator

How ZTALMY Works

While the precise mechanism of ganaxolone is unknown, its therapeutic effects are thought to result from its activity in the central nervous system. The drug acts as a positive allosteric modulator of the gamma-aminobutyric acid type A (GABA A) receptor. By modulating these receptors, the medication produces anticonvulsant effects to help manage seizures.

2
Indications
--
Phase 3 Trials
1
Priority Reviews
4
Years on Market

Details

Status
Prescription
First Approved
2022-03-18
Routes
ORAL
Dosage Forms
SUSPENSION

Companies

Active Ingredient: GANAXOLONE

ZTALMY Approval History

Loading approval history...

What ZTALMY Treats

2 indications

ZTALMY is approved for 2 conditions since its original approval in 2022. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Seizures
  • Cyclin-Dependent Kinase-Like 5 Deficiency Disorder
Source: FDA Label

Drugs Similar to ZTALMY

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AFINITOR
EVEROLIMUS
1 shared
Novartis
Shared indications:
Seizures
BANZEL
RUFINAMIDE
1 shared
EISAI INC
Shared indications:
Seizures
CEREBYX
FOSPHENYTOIN SODIUM
1 shared
PARKE DAVIS
Shared indications:
Seizures
DIASTAT ACUDIAL
DIAZEPAM
1 shared
BAUSCH
Shared indications:
Seizures
DIAZEPAM INTENSOL
DIAZEPAM
1 shared
Hikma
Shared indications:
Seizures
EPIDIOLEX
CANNABIDIOL
1 shared
JAZZ PHARMS RES
Shared indications:
Seizures
FENFLURAMINE
FENFLURAMINE
1 shared
Apotex
Shared indications:
Seizures
FINTEPLA
FENFLURAMINE HYDROCHLORIDE
1 shared
UCB INC
Shared indications:
Seizures
MAGNESIUM SULFATE
MAGNESIUM SULFATE
1 shared
ASPIRO
Shared indications:
Seizures
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
MAGNESIUM SULFATE
1 shared
Baxter
Shared indications:
Seizures
MAGNESIUM SULFATE IN PLASTIC CONTAINER
MAGNESIUM SULFATE
1 shared
GLAND
Shared indications:
Seizures
METHSUXIMIDE
METHSUXIMIDE
1 shared
NOVITIUM PHARMA
Shared indications:
Seizures
NAYZILAM
MIDAZOLAM
1 shared
UCB INC
Shared indications:
Seizures
ONFI
CLOBAZAM
1 shared
LUNDBECK PHARMS LLC
Shared indications:
Seizures
PHENYTEK
PHENYTOIN SODIUM
1 shared
Viatris
Shared indications:
Seizures
PHENYTOIN
PHENYTOIN
1 shared
EPIC PHARMA LLC
Shared indications:
Seizures
RUFINAMIDE
RUFINAMIDE
1 shared
PHARMOBEDIENT
Shared indications:
Seizures
SUPREP BOWEL PREP KIT
MAGNESIUM SULFATE
1 shared
AZURITY
Shared indications:
Seizures
SYMPAZAN
CLOBAZAM
1 shared
ASSERTIO SPECLTY
Shared indications:
Seizures
TIS-U-SOL IN PLASTIC CONTAINER
MAGNESIUM SULFATE
1 shared
Baxter
Shared indications:
Seizures
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ZTALMY FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

ZTALMY is indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older. ZTALMY is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older.

ZTALMY Patents & Exclusivity

Latest Patent: Sep 2042
Exclusivity: May 2029

Patents (11 active)

US12115169 Expires Sep 30, 2042
US12268696 Expires Sep 30, 2042
US12144801 Expires Aug 10, 2037
US10603308 Expires Aug 10, 2037
US8618087 Expires Nov 28, 2026
US9056116 Expires Nov 28, 2026
US7858609 Expires Nov 28, 2026
US8022054 Expires Nov 28, 2026
US8367651 Expires Nov 28, 2026
US9029355 Expires Nov 28, 2026
+ 1 more patents

Exclusivity

D-197 Until Oct 2028
NCE Until Jun 2027
ODE-395 Until Jun 2029
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.